ERAS
Price
$1.06
Change
-$0.13 (-10.83%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
337.09M
28 days until earnings call
LRMR
Price
$1.78
Change
-$0.10 (-5.32%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
120.05M
28 days until earnings call
Ad is loading...

ERAS vs LRMR

Header iconERAS vs LRMR Comparison
Open Charts ERAS vs LRMRBanner chart's image
Erasca
Price$1.06
Change-$0.13 (-10.83%)
Volume$16.27K
Capitalization337.09M
Larimar Therapeutics
Price$1.78
Change-$0.10 (-5.32%)
Volume$17.47K
Capitalization120.05M
ERAS vs LRMR Comparison Chart
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. LRMR commentary
Apr 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and LRMR is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 11, 2025
Stock price -- (ERAS: $1.19 vs. LRMR: $1.88)
Brand notoriety: ERAS and LRMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 162% vs. LRMR: 277%
Market capitalization -- ERAS: $337.09M vs. LRMR: $120.05M
ERAS [@Biotechnology] is valued at $337.09M. LRMR’s [@Biotechnology] market capitalization is $120.05M. The market cap for tickers in the [@Biotechnology] industry ranges from $281.65B to $0. The average market capitalization across the [@Biotechnology] industry is $2.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileLRMR’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • LRMR’s FA Score: 1 green, 4 red.
According to our system of comparison, both ERAS and LRMR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 3 TA indicator(s) are bullish while LRMR’s TA Score has 3 bullish TA indicator(s).

  • ERAS’s TA Score: 3 bullish, 4 bearish.
  • LRMR’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, LRMR is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а -5.56% price change this week, while LRMR (@Biotechnology) price change was -14.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.53%. For the same industry, the average monthly price growth was -18.05%, and the average quarterly price growth was -19.90%.

Reported Earning Dates

ERAS is expected to report earnings on Aug 07, 2025.

LRMR is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-7.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($337M) has a higher market cap than LRMR($120M). LRMR (-51.550) and ERAS (-52.590) have similar YTD gains . LRMR has higher annual earnings (EBITDA): -73.44M vs. ERAS (-151.33M). ERAS has more cash in the bank: 319M vs. LRMR (204M). LRMR has less debt than ERAS: LRMR (5.36M) vs ERAS (52.9M). ERAS (0) and LRMR (0) have equivalent revenues.
ERASLRMRERAS / LRMR
Capitalization337M120M281%
EBITDA-151.33M-73.44M206%
Gain YTD-52.590-51.550102%
P/E RatioN/AN/A-
Revenue00-
Total Cash319M204M156%
Total Debt52.9M5.36M987%
FUNDAMENTALS RATINGS
LRMR: Fundamental Ratings
LRMR
OUTLOOK RATING
1..100
65
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
97
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASLRMR
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FADCX21.88N/A
N/A
Fidelity Advisor Diversified Intl C
ADGAX19.89N/A
N/A
AB Core Opportunities A
MITHX30.92N/A
N/A
MFS Massachusetts Investors Tr R3
STVTX8.68N/A
N/A
Virtus Ceredex Large-Cap Value Equity I
SLVCX14.56N/A
N/A
Saratoga Large Capitalization Value C

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+12.26%
XNCR - ERAS
51%
Loosely correlated
+14.86%
KYMR - ERAS
51%
Loosely correlated
+13.78%
RVMD - ERAS
50%
Loosely correlated
+12.82%
RCKT - ERAS
49%
Loosely correlated
+12.53%
IMNM - ERAS
49%
Loosely correlated
+11.69%
More

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with SVRA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then SVRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
+9.65%
SVRA - LRMR
46%
Loosely correlated
+5.00%
IMNM - LRMR
44%
Loosely correlated
+11.69%
ACLX - LRMR
44%
Loosely correlated
+10.37%
ERAS - LRMR
44%
Loosely correlated
+12.26%
DNTH - LRMR
42%
Loosely correlated
+9.83%
More